<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852861</url>
  </required_header>
  <id_info>
    <org_study_id>DemiVac2021</org_study_id>
    <secondary_id>2021-002088-23</secondary_id>
    <nct_id>NCT04852861</nct_id>
  </id_info>
  <brief_title>COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine</brief_title>
  <acronym>REDU-VAC</acronym>
  <official_title>COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciensano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mensura EDPB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sciensano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase IV dose-optimization study evaluating the safety and&#xD;
      immunogenicity of two doses of COVID-19 mRNA vaccines being authorized in the European Union&#xD;
      since December 2020: Vaccine BNT162b2 (Comirnaty®; Pfizer-BioNTech) in healthy adults up to&#xD;
      age 55 year. Immunogenicity will be measured 28 days after first and second dose, and day 180&#xD;
      and day 365 after first vaccination of 20 and 30 mcg of BNT162b2. The primary outcome is the&#xD;
      level of binding antibodies for RBD 28 days after the second dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Data from the dose-escalating phase 1 trials from the COVID-19 mRNA vaccines&#xD;
      being authorized in the European Union since December 2020, BNT162b2 (Comirnaty®; Pfizer-&#xD;
      BioNTech) indicate that for the age group 18-55 years a lower dose of the vaccine can induce&#xD;
      the same immune response as the full dose.&#xD;
&#xD;
      Method: This is a randomized multicenter phase IV dose-optimization study evaluating the&#xD;
      safety and immunogenicity of demi-doses of a COVID-19 mRNA vaccine being authorized in the&#xD;
      European Union since December 2020, BNT162b2 (Comirnaty®; Pfizer- BioNTech) in healthy adults&#xD;
      up to age 55 year. The study will be performed in employees of Mensura EDPB at five different&#xD;
      sites.&#xD;
&#xD;
      Objectives: The primary outcome is the level of binding antibodies for RBD 28 days after the&#xD;
      second dose. Secondary outcomes are safety and reactogenicity after vaccination. The&#xD;
      neutralizing antibodies and the cellular immunity 28 days after second dose will be assessed.&#xD;
      Humoral and cellular immunity will be measured 180 and 365 days after first dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The research nurse administrating the vaccine is the only one who is not blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titre (GMT) of Binding antibodies to the RBD of SARS-CoV-2 S protein</measure>
    <time_frame>28 days after second dose</time_frame>
    <description>Binding antibodies anti-RBD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of Neutralizing anti-bodies to Wuhan strain and variants</measure>
    <time_frame>28 days after second dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell response to S protein of Wuhan strain and variants and Memory B cell responses to S protein of Wuhan strain and variants</measure>
    <time_frame>28 days after second dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral and cellulair immunity</measure>
    <time_frame>180 days after first dose</time_frame>
    <description>GMT of of Binding antibodies to the RBD of SARS-CoV-2 S protein and Neutralizing anti-bodies to Wuhan strain and variants and T cell response to S protein of Wuhan strain and variants and Memory B cell responses to S protein of Wuhan strain and variants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral and cellulair immunity</measure>
    <time_frame>365 days after first dose</time_frame>
    <description>GMT of of Binding antibodies to the RBD of SARS-CoV-2 S protein and Neutralizing anti-bodies to Wuhan strain and variants and T cell response to S protein of Wuhan strain and variants and Memory B cell responses to S protein of Wuhan strain and variants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and reactogenicity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>adverse events will be followed up after vaccine adminstration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 20 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 30 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 30 mcg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>immunogenicity after first and second dose</intervention_name>
    <description>Humoral and cellulair immunity after first and second dose of the different vaccines administrated.</description>
    <arm_group_label>Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 20 mcg</arm_group_label>
    <arm_group_label>Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 30 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Working at Mensura EDPB, not yet vaccinated for COVID19 -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mensura EDPB</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sciensano</investigator_affiliation>
    <investigator_full_name>Maria Goossens</investigator_full_name>
    <investigator_title>Scientific collaborator</investigator_title>
  </responsible_party>
  <keyword>vaccination</keyword>
  <keyword>Covid19</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

